BioWest Venture Showcase
These 6 selected start‐up company finalists pitch their technologies and business plans in front of a live audience to a panel of bioscience experts and venture capitalists. The winner will receive a $7,500 cash prize at the competition.
Flashback Technologies, Inc.
Flashback Technologies, Inc. is developing and commercializing product applications of its novel, proprietary machine-learning software algorithm platform called CipherSensorTM Technology. The CipherSensor computational
engine has the potential to provide groundbreaking, predictive "big data" analytical solutions across a variety of industries where making sense of growing volumes of industry-specific data is an increasing challenge in assuring optimal quality processes, productivity and outcomes. The Company's first product application is in the medical trauma setting enabling the immediate, noninvasive detection of the risk for cardiovascular collapse and monitoring of the effectiveness of fluid resuscitation therapy.
KromaTiD makes products for analyzing defects and damage to human chromosomes. In 2012, we are launching the first commercial platform for the discovery and detection of a recalcitrant class of DNA mutations known as Chromosomal Inversions. Inversions cause diseases, and our products have research and diagnostic applications in oncology, developmental disorders, infertility and other clinical conditions. KromaTiD supplies reagents, kits and custom probes to academic, government and commercial researchers worldwide. KromaTiD technology is licensed from CSU, and has been developed with support from NASA, Colorado State University, the State of Colorado and CID4. www.kromatid.com
Siva Therapeutics Inc.
Siva Therapeutics is developing a method for cancer therapy which promises to be safer, with fewer side effects, and at least as effective as current therapies. Siva’s approach is precision photothermal treatment of solid tumors using targeted gold nanorods - SivaRods™. The SivaRods™ efficiently absorb infrared light, and emit heat localized to the tumor mass. Our initial market will be skin cancer, where we believe our therapy will provide the best course of treatment for approximately 50% of the 70,000 melanoma cases in the US annually, and some 10% of all skin cancer cases, generating potential revenue of $340 million.
SuviCa is a biotechnology company focused on the discovery and development of small molecule drugs for oncology. SuviCa’s family of compounds target a process crucial for cancer growth but under-utilized as a drug target. Using a proprietary screen, SuviCa has identified a lead compound targeted for glioblastoma and head and neck cancer, a second clinical candidate targeted for a larger patient population such as lung cancer, and new chemical entities as follow-on candidates. SuviCa is led by an outstanding science and management team. SuviCa has a strong patent portfolio and has raised more than $750K through non-dilutive funding and state grants.
VetDC is an emergent veterinary biotechnology company that licenses innovative human biomedical technologies to address serious unmet medical needs in companion animals. By aligning with CSU's top-ranked veterinary school, VetDC has unique capabilities to develop animal therapies, resulting in speed to market, risk reduction, and capital preservation. VetDC has assembled a proven team with regulatory, CMC, and clinical expertise. Our lead candidate, VDC-1101, is a novel anti-cancer drug with extensive animal data. VDC-1101 is expected to launch in 2014 with $50M peak revenue potential. In 2011, VetDC secured funding from the Colorado Institute for Drug, Device and Diagnostic Development (CID4).